From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursorprotein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ. Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research .
ELN318463 is an amyloidprecursorprotein (APP) selective γ-secretase inhibitor. ELN318463 shows differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC50s of 12 nM and 656 nM for PS1 and PS2, respectively. ELN318463 is 51-fold more selective for PS1 .
Etazolate hydrochloride (SQ 20009) is an orally active, selective inhibitor of type 4 phosphodiesterase (PDE4) with an IC50 of 2 μM. Etazolate hydrochloride is a γ-aminobutyric acid A (GABAA) receptor regulator. Etazolate hydrochloride is an α-secretase activator and induced the production of soluble amyloidprecursorprotein (sAPPα). Etazolate hydrochloride, a pyrazolopyridine class derivative, increases cAMP levels. Etazolate hydrochloride has anxiolyticlike, antidepressant-like and anti-inflammatory effects .
Glp-Amyloid-β (3-40) Peptide (human) (AβpE3-40) is a minor amounts of pyroglutamate-modified Aβ isolated from from 24-month-old Amyloidprecursorprotein (APP) transgenic Mice .
Amyloid 17-42 (Aβ(17-42)) is a major constituent of diffuse plaques in Alzheimer's disease and cerebellar pre-amyloid in Down's syndrome, derived by alpha- and gamma-secretase cleavage of the amyloidprecursorprotein (APP). Amyloid 17-42 can induce neuronal apoptosis via a Fas-like/caspase-8 activation pathway .
ELN318463 racemate is the racemate of ELN318463. ELN318463 is an amyloidprecursorprotein (APP) selective γ-secretase inhibitor. ELN318463 shows differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC50s of 12nM and 656 nM for PS1and PS2, respectively. ELN318463 is 51-fold more selective for PS1 .
Amyloidprecursor C-terminal peptide is cleaved from the C-terminus of AmyloidPrecursorProtein (APP). Amyloidprecursor C-terminal peptide accumulation causes mitochondrial morphology alteration and basal mitophagy failure, which indicates that amyloidprecursorprotein C-terminal peptide may correspond to an etiological trigger of Alzheimer’s disease (AD) pathology .
Etazolate (hydrochloride) (Standard) is the analytical standard of Etazolate (hydrochloride). This product is intended for research and analytical applications. Etazolate hydrochloride (SQ 20009) is an orally active, selective inhibitor of type 4 phosphodiesterase (PDE4) with an IC50 of 2 μM. Etazolate hydrochloride is a γ-aminobutyric acid A (GABAA) receptor regulator. Etazolate hydrochloride is an α-secretase activator and induced the production of soluble amyloidprecursorprotein (sAPPα). Etazolate hydrochloride, a pyrazolopyridine class derivative, increases cAMP levels. Etazolate hydrochloride has anxiolyticlike, antidepressant-like and anti-inflammatory effects .
δ-Secretase inhibitor 11 (compound 11) is an orally active, potent, BBB-penetrated, non-toxic, selective and specific δ-secretase inhibitor, with an IC50 of 0.7 μM. δ-Secretase inhibitor 11 interacts with both the active site and allosteric site of δ-secretase. δ-Secretase inhibitor 11 attenuates tau and APP (amyloidprecursorprotein) cleavage. δ-Secretase inhibitor 11 ameliorates synaptic dysfunction and cognitive impairments in tau P301S and 5XFAD transgenic mouse models. δ-Secretase inhibitor 11 can be used for Alzheimer's disease research .
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-β(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloidprecursorprotein (APP) .
Latrepirdine is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloidprecursorprotein (APP) catabolism and amyloid-β (Aβ) secretion.
Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloidprecursorprotein (APP) catabolism and amyloid-β (Aβ) secretion.
Buntanetap ((+)-Phenserine) is a selective acetylcholinesterase inhibitor. Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloidprecursorprotein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloidprecursorprotein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .
β-Amyloid/A4 Protein Precusor (319-335) (APP (319-335)) is a peptide fragment of β-Amyloid/A4 proteinprecursor (APP). β-Amyloid/A4 Protein Precusor (319-335) can recognize the heparinase-insensitive site that contains the neuritotropic activity of APP .
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursorprotein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
Buntanetap L-Tartrate (Phenserine L-Tartrate) is a selective AChE inhibitor (IC50 = 22.2 nM). Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloidprecursorprotein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloidprecursorprotein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .
AZ4800 is a combined inhibitor of two targets in the amyloidprecursorprotein processing process with additive lowering activity on Aβ42 levels in vitro and in vivo.
JLK-6 markedly reduce the production of amyloid β-peptide (Aβ) by amyloid-β Precursorprotein (APP) expressing HEK293 cells by affecting the γ-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor .
APP669-711 is a peptide segment from amino acid 669 to amino acid 711 of amyloidprecursorprotein (APP). APP669-711 can be used to diagnose the amyloid deposition in the brain, and is a biomarker for Alzheimer's disease (AD) research .
BMS 299897 is a sulfonamide γ-secretase inhibitor with an IC50 of 7 nM for Aβ production inhibition in HEK293 cells stably overexpressing amyloidprecursorprotein (APP).
RERMS are bioactive peptides produced from the active regions of amyloid-β and A4 proteinprecursors that promote fibroblast growth and can be used in the study of neurodegenerative diseases .
DSS30 is a P25/CDK5 inhibitor that reduces β-amyloid (Aβ) secretion by inhibiting amyloidprecursorprotein lyase 1 (BACEl) phosphorylation. DSS30 can be used in the study of neurodegenerative diseases such as Alzheimer's disease .
AZD3839 is an orally available, selective, reversible inhibitor of the β-site amyloidprecursorprotein cleaving enzyme BACE1 that can cross the blood-brain barrier. AZD3839 inhibits recombinant human BACE1 with a Ki=26.1 nM. AZD3839 inhibits A40 production in SH-SY5Y cells with an IC50 of 4.8 nM. AZD3839 binds to BACE1 and reduces the Aβ amyloid produced by the cleavage of amyloidprecursorprotein (APP) by BACE1 and γ-secretase. AZD3839 can be used in the field of Alzheimer's disease research .
Phenserine ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine reduces β-amyloidprecursorprotein (APP) and β-amyloid peptide (Aβ) formation. Phenserine improves cognitive performance and attenuates the progression of Alzheimer's disease .
PF-06751979 is a potent, brain penetrant, β-site amyloidprecursorprotein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 7.3 nM in BACE1 binding assay.
cis-Miyabenol C is an isomer of the resveratrol trimer Miyabenol C, which can be isolated from grape herbs. Miyabenol C is an inhibitor of β-amyloid (Aβ) and amyloid β precursorprotein (APP) in Alzheimer's disease model mice, and inhibit β-secretase activity without changing the protein level of β-secretase BACE1 .
Phenserine tartrate ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine tartrate reduces β-amyloidprecursorprotein (APP) and β-amyloid peptide (Aβ) formation. Phenserine tartrate improves cognitive performance and attenuates the progression of Alzheimer's disease .
Mca-SEVKMDAEFRK(Dnp)RR-NH2, containing the wild-type amyloidprecursorprotein (APP) beta-secretase cleavage site, is the substrate of thimet oligopeptidase (TOP). It is used for Alzheimer's disease research .
AZ-4217 is an inhibitor for β-site amyloidprecursorprotein cleavage enzyme 1 (BACE1), with IC50 of 160 pM in human SH-SY5Y cells. AZ-4217 reduces amyloid deposition in Tg2576 mouse models, and is used for Alzheimer’s Disease research .
TML-6-d3 is the deuterium labeled TML-6. TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloidprecursorprotein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-
Scoulerine ((-)-Scoulerine), an isoquinoline alkaloid, is a potent antimitotic compound. Scoulerine is also an inhibitor of BACE1 (?-site amyloidprecursorprotein cleaving enzyme 1). Scoulerine inhibits proliferation, arrests cell cycle, and induces apoptosis in cancer cells .
TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloidprecursorprotein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-oxidative Nrf2 gene. TML-6 has the potential for Alzheimer’s disease (AD) research .
BACE1-IN-5 (Compound 15) is a β-site amyloidprecursorprotein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 9.1 nM, and also inhibits cellular amyloid-β (Aβ) with an IC50 of 0.82 nM. BACE1-IN-5 has a medicinal chemistry that improves hERG inhibition and P-gp efflux .
(R)-(+)-Anatabine is an less active R-enantiomer of Anatabine. Anatabine is a potent α4β2 nAChR agonist . Anatabine inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloidprecursorprotein (APP). Anatabine has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment .
EHT 1864 is an inhibitor of Rac family small GTPases. EHT 1864 directly binds and impairs the ability of this small GTPase to engage critical downstream effectors required for growth transformation. The Kd values are 40, 50, 60, and 230 nM for Rac1, Rac1b, Rac2 and Rac3, respectively. EHT 1864 also potently inhibits other Rac-dependent transformation processes, Tiam1- and Ras-mediated growth transformation. EHT 1864 prevents Aβ 40 and Aβ 42 production in vivo. EHT 1864 dependently suppresses the release of migrasomes from podocytes induced by LPS, PAN, or HG .
α-Secretase Substrate II, Fluorogenic is an internally quenched fluorogenic peptide substrate for α-Secretase that contains the α-secretase cleavage site of β-Amyloidprecursorprotein (APP) .Ex/Em = 340/490 nm
Fmoc-Ala-Glu-Asn-Lys-NH2 is a selective asparagine endopeptidase (AEP) inhibitor peptide and suppresses amyloidprecursorprotein (APP) cleavage. AEP, a pH-controlled cysteine proteinase, is activated during ageing and mediates APP proteolytic processing .
Aβ aggregation-IN-1 (Compound 1b) is an amyloid-betaprecursorprotein inhibitor. Aβ aggregation-IN-1 inhibits amyloid-beta aggregation and disaggregation of fibrillogenesis with IC50 values of 3.92 and 7.19 M, respectively. Aβ aggregation-IN-1 also inhibits malondialdehyde formation, augments the intracellular reduced glutathione (GSH) levals and inhibits caspase 3 in neuronal cells .
BACE-IN-1 (Compound 13) is a substituted lmidazo[1 ,2-a]pyridine derivative which can inhibit β-site amyloidprecursorprotein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease.
Anatabine dicitrate is a tobacco alkaloid that can cross the blood-brain barrier. Anatabine dicitrate is a potent α4β2 nAChR agonist. Anatabine dicitrate inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloidprecursorprotein (APP). Anatabine dicitrate has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment .
Amyloid β-Protein (3-42) TFA is a precursor of Pyr peptide. Pyroglutamic acid-modified Aβ (pEAβ) (3-42) is the core of the amyloid plaque in Alzheimer's disease. pEAβ (3-42) accelerates the aggregation of Aβ(1-42), while Aβ(1-42) significantly slows down the primary and secondary nucleation of pEAβ(3-42).
Umibecestat (CNP520) is a beta-site amyloidprecursorprotein cleaving enzyme-1 (BACE-1) inhibitor with IC50s of 11 nM and 10 nM for human BACE-1 and mouse BACE-1, respectively . Umibecestat can be used for the research of alzheimer's disease.
Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42) .
BCA (Disodium bicinchoninate) is an orally active and non-competitive Beta-site amyloidprecursorprotein cleaving enzyme 1 (BACE1) inhibitor with an IC50 value of 28 µM, a Ki value of 43 µM. BCA shows anticancer activity. BCA has the potential for the research of Alzheimer's disease (AD) .
Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloidprecursorprotein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment .
(Rac)-AZD3839 is an orally active beta-amyloidprecursorprotein cleaving enzyme (BACE1) inhibitor that is blood-brain barrier-permeable. (Rac)-AZD3839 has an affinity for the human ether-a-go-go related gene (hERG) ion channel. (Rac)-AZD3839 can be used in the research of Alzheimer's disease .
APP degrader-1 (Compound 0152) is an orally active amyloidprecursorprotein (APP) degrader that induces APP degradation and reduces the extracellular release of Aβ42. APP degrader-1 can bind to both CAPRIN1 and APP, and enhances their interaction as well as CAPRIN1-mediated APP degradation through the endosome-lysosome pathway .
gamma-secretase modulator 6 (Example 50) is a gamma-secretase modulator. gamma-secretase modulator 6 inhibits Aβ42 secretion in HEK cell line stably expressing APP (Aβ amyloidprecursorprotein) (pIC50: 8.1). gamma-secretase modulator 6 can be used for research of Alzheimer's disease .
BACE1-IN-15 (Compound 72) is a selective inhibitor of beta-site amyloidprecursorprotein cleaving enzyme 1 (BACE-1) with oral activity and the ability to penetrate the blood-brain barrier. Its IC50 value is 121.65 nM (the IC50 value for BACE-2 is 480.92 nM). BACE1-IN-15 can be used in the research of the Alzheimer's disease field
NB-360 is a potent, brain penetrable, and orally bioavailable dual BACE1/BACE2 inhibitor (IC50: mouse and human BACE1=5 nM; BACE2=6 nM). NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in amyloidprecursorprotein(APP) transgenic mice. NB-360 can completely block the progression of Aβ deposition in the brains of APP transgenic mice. NB-360 shows excellent selectivity over the related aspartyl proteases pepsin, cathepsin D and cathepsin E .
LY2886721 hydrochloride is a potent, selective and orally active beta-site amyloidprecursorprotein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 20.3 nM for recombinant human BACE1. LY2886721 hydrochloride is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC50 of 10.2 nM). LY2886721 hydrochloride can across blood-brain barrier and has the potential for Alzheimer's disease treatment .
LY2886721 is a potent, selective and orally active beta-site amyloidprecursorprotein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 20.3 nM for recombinant human BACE1. LY2886721 is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC50 of 10.2 nM). LY2886721 can across blood-brain barrier and has the potential for Alzheimer's disease treatment .
AM-6494 is a potent and orally active BACE1 (efficacious β-site amyloidprecursorprotein cleaving enzyme 1) inhibitor (IC50=0.4 nM) with in vivo selectivity over BACE2 (IC50=18.6 nM) . AM-6494 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Mca-SEVNLDAEFK(Dnp) is a Beta-secretase 1 (BACE-1) peptide FRET substrate, containing the 'Swedish' Lys-Met/Asn-Leu mutation of the amyloidprecursorprotein (APP) β-secretase cleavage site. Cleavage at -Leu-Asp- of Mca-SEVNLDAEFK(Dnp) liberates the highly fluorescent 7-methoxycoumarin (Mca) fragment from the proximity quenching effect of the 2,4-dinitrophenyl (Dnp) internal quencher resulting in a large and easily detectable increase in fluorescence intensity.
Cholesterol Excipient is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity. Cholesterol Excipient is a drug delivery carrier based on the lipid environment of the cell membrane. Due to its amphiphilicity, good biocompatibility and biodegradability, it can be used as an excipient in drug preparations. Cholesterol Excipient can self-assemble into delivery systems such as micelles, nanoparticles, and liposomes, and achieve controlled drug release by regulating membrane fluidity or responding to the microenvironment. It has the characteristics of high drug loading efficiency and good biocompatibility. Cholesterol Excipient is mainly used for research in the fields of targeted delivery of anticancer, antibacterial, antiviral drugs and treatment of skin diseases.
Cholesterol itself is also an endogenous regulator involved in the cleavage of amyloidprecursorprotein (APP) mediated by β-secretase and intestinal absorption, as well as an endogenous estrogen-related receptor α (ERRα) agonist. Cholesterol affects the subcellular localization of APP processing enzymes by regulating the cell membrane lipid environment, which can promote the production of β-amyloidprotein and its adsorption and removal by probiotics. It is used to study the pathogenesis of Alzheimer's disease (AD) and the cholesterol-lowering function of probiotics[1][2][3][4][5].
D-688 is an inhibitor of Tau and Aβ. D-688 can reverse Aβ1–42-induced toxicity in SH-SH5Y cells and has significant neuroprotective properties. D-688 can improve the survival rate of Drosophila melanogaster expressing the human tau protein isoform (2N4R) .
Cholesterol (Excipient) (Standard) is the analytical standard of Cholesterol (Excipient) (HY-N0322B). This product is intended for research and analytical applications. Cholesterol Excipient is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity. Cholesterol Excipient is a drug delivery carrier based on the lipid environment of the cell membrane. Due to its amphiphilicity, good biocompatibility and biodegradability, it can be used as an excipient in drug preparations. Cholesterol Excipient can self-assemble into delivery systems such as micelles, nanoparticles, and liposomes, and achieve controlled drug release by regulating membrane fluidity or responding to the microenvironment. It has the characteristics of high drug loading efficiency and good biocompatibility. Cholesterol Excipient is mainly used for research in the fields of targeted delivery of anticancer, antibacterial, antiviral drugs and treatment of skin diseases.
Cholesterol itself is also an endogenous regulator involved in the cleavage of amyloidprecursorprotein (APP) mediated by β-secretase and intestinal absorption, as well as an endogenous estrogen-related receptor α (ERRα) agonist. Cholesterol affects the subcellular localization of APP processing enzymes by regulating the cell membrane lipid environment, which can promote the production of β-amyloidprotein and its adsorption and removal by probiotics. It is used to study the pathogenesis of Alzheimer's disease (AD) and the cholesterol-lowering function of probiotics[1][2][3][4][5].
ML 10302 hydrochloride is a potent and selective 5-HT4 receptor agonist, with an EC50 of 4 nM. ML 10302 hydrochloride displays more than 680-fold selectivity over 5-HT3 receptor in binding assay .
L-685458 is a potent transition state analog (TSA) γ-secretase inhibitor (GSI). L-685458 inhibits amyloid β-proteinprecursor γ-secretase activity with IC50 of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L685458 inhibits γ-secretase-mediated cleavage of APP-C99 and Notch-100 with IC50s of 301.3 nM and 351.3 nM, respectively. L-685458 can be used for the research of alzheimer’s disease (AD) and cancers .
BACE2-IN-1 (compound 3l) is a highly selective BACE2 inhibitor with a K i value of 1.6 nM. BACE2 inhibitors can be used to research of Type 2 Diabetes .
BCA (Disodium bicinchoninate) is an orally active and non-competitive Beta-site amyloidprecursorprotein cleaving enzyme 1 (BACE1) inhibitor with an IC50 value of 28 µM, a Ki value of 43 µM. BCA shows anticancer activity. BCA has the potential for the research of Alzheimer's disease (AD) .
β-Amyloidprecursorprotein (96-110), cyclized (human) is an amyloidprecursorprotein. β-Amyloidprecursorprotein (96-110), cyclized (human) can be used in study Alzheimer’s disease .
Glp-Amyloid-β (3-40) Peptide (human) (AβpE3-40) is a minor amounts of pyroglutamate-modified Aβ isolated from from 24-month-old Amyloidprecursorprotein (APP) transgenic Mice .
Amyloid 17-42 (Aβ(17-42)) is a major constituent of diffuse plaques in Alzheimer's disease and cerebellar pre-amyloid in Down's syndrome, derived by alpha- and gamma-secretase cleavage of the amyloidprecursorprotein (APP). Amyloid 17-42 can induce neuronal apoptosis via a Fas-like/caspase-8 activation pathway .
Amyloidprecursor C-terminal peptide is cleaved from the C-terminus of AmyloidPrecursorProtein (APP). Amyloidprecursor C-terminal peptide accumulation causes mitochondrial morphology alteration and basal mitophagy failure, which indicates that amyloidprecursorprotein C-terminal peptide may correspond to an etiological trigger of Alzheimer’s disease (AD) pathology .
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-β(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloidprecursorprotein (APP) .
β-Amyloid/A4 Protein Precusor (319-335) (APP (319-335)) is a peptide fragment of β-Amyloid/A4 proteinprecursor (APP). β-Amyloid/A4 Protein Precusor (319-335) can recognize the heparinase-insensitive site that contains the neuritotropic activity of APP .
APP669-711 is a peptide segment from amino acid 669 to amino acid 711 of amyloidprecursorprotein (APP). APP669-711 can be used to diagnose the amyloid deposition in the brain, and is a biomarker for Alzheimer's disease (AD) research .
RERMS are bioactive peptides produced from the active regions of amyloid-β and A4 proteinprecursors that promote fibroblast growth and can be used in the study of neurodegenerative diseases .
Mca-SEVKMDAEFRK(Dnp)RR-NH2, containing the wild-type amyloidprecursorprotein (APP) beta-secretase cleavage site, is the substrate of thimet oligopeptidase (TOP). It is used for Alzheimer's disease research .
[Asn23] β-Amyloid (1-40), Iowa mutation is a biological active peptide. (Several mutations in the beta amyloidprecursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds. The Iowa mutation, where Asp 23 is replaced with Asn, is associated with severe cerebral amyloid beta-protein angiopathy (CAA). The affected individuals share a missense mutation in APP at position 694. The mutated beta-amyloid peptide aggregates more rapidly and forms toxic fibrils.)
[Asn23]-beta-Amyloid (1-42), iowa mutation is a biological active peptide. (Several mutations in the beta amyloidprecursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds. The Iowa mutation, where Asp 23 is replaced with Asn, is associated with severe cerebral amyloid beta-protein angiopathy (CAA). The affected individuals share a missense mutation in APP at position 694. The mutated beta-amyloid peptide aggregates more rapidly and forms toxic fibrils.)
α-Secretase Substrate II, Fluorogenic is an internally quenched fluorogenic peptide substrate for α-Secretase that contains the α-secretase cleavage site of β-Amyloidprecursorprotein (APP) .Ex/Em = 340/490 nm
Fmoc-Ala-Glu-Asn-Lys-NH2 is a selective asparagine endopeptidase (AEP) inhibitor peptide and suppresses amyloidprecursorprotein (APP) cleavage. AEP, a pH-controlled cysteine proteinase, is activated during ageing and mediates APP proteolytic processing .
Amyloid β-Protein (3-42) TFA is a precursor of Pyr peptide. Pyroglutamic acid-modified Aβ (pEAβ) (3-42) is the core of the amyloid plaque in Alzheimer's disease. pEAβ (3-42) accelerates the aggregation of Aβ(1-42), while Aβ(1-42) significantly slows down the primary and secondary nucleation of pEAβ(3-42).
Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42) .
Mca-SEVNLDAEFK(Dnp) is a Beta-secretase 1 (BACE-1) peptide FRET substrate, containing the 'Swedish' Lys-Met/Asn-Leu mutation of the amyloidprecursorprotein (APP) β-secretase cleavage site. Cleavage at -Leu-Asp- of Mca-SEVNLDAEFK(Dnp) liberates the highly fluorescent 7-methoxycoumarin (Mca) fragment from the proximity quenching effect of the 2,4-dinitrophenyl (Dnp) internal quencher resulting in a large and easily detectable increase in fluorescence intensity.
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursorprotein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ. Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research .
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursorprotein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
Scoulerine ((-)-Scoulerine), an isoquinoline alkaloid, is a potent antimitotic compound. Scoulerine is also an inhibitor of BACE1 (?-site amyloidprecursorprotein cleaving enzyme 1). Scoulerine inhibits proliferation, arrests cell cycle, and induces apoptosis in cancer cells .
cis-Miyabenol C is an isomer of the resveratrol trimer Miyabenol C, which can be isolated from grape herbs. Miyabenol C is an inhibitor of β-amyloid (Aβ) and amyloid β precursorprotein (APP) in Alzheimer's disease model mice, and inhibit β-secretase activity without changing the protein level of β-secretase BACE1 .
Amyloid Precursor/APP-695 Protein, Human (HEK293, Fc) is an Amyloid Precursor (APP) protein with C-Fc. Amyloid Precursor Protein can be used for the study of brain development, learning and memory, synaptic plasticity, and neurodegeneration.
There is no specific Pubmed ID mentioned in the paragraph. Amyloid Precursor/Beta-APP42 Protein, Human (His-GST) is the recombinant human-derived Amyloid Precursor/Beta-APP42 protein, expressed by E. coli , with N-His, N-GST labeled tag.
There is no specific Pubmed ID mentioned in the paragraph. Amyloid Precursor/APP-751 Protein, Human (HEK293, Fc) is the recombinant human-derived APP-751 protein, expressed by HEK293 , with C-hFc labeled tag.
APLP-1 protein is involved in postsynaptic function and synaptic processes. Its processing produces ALID1, which activates transcription through APBB1 binding. APLP-1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived APLP-1 protein, expressed by HEK293 , with C-His labeled tag.
The APPBP1-UBA3/NEDD8 E1 protein is the regulatory subunit in the UBA3-NAE1 E1 enzyme complex and activates NEDD8 by adenylating its C-terminal glycine with ATP. This forms the NEDD8-UBA3 thioester, which is transferred to the catalytic cysteine of UBE2M. APPBP1-UBA3/NEDD8 E1 Protein, Human is a recombinant protein dimer complex containing human-derived APPBP1-UBA3/NEDD8 E1 protein, expressed by E. coli , with tag free. APPBP1-UBA3/NEDD8 E1 Protein, Human, has molecular weight of 60 kDa (APP-BP1) 50 kDa (UBA3).
SNCA proteins are critical for synaptic activity and regulate vesicle trafficking and neurotransmitter release. As a monomer, it enhances the vesicle exocytosis process. SNCA Protein, Mouse is the recombinant mouse-derived SNCA protein, expressed by E. coli , with tag free.
SNCA Protein is a protein abnormally aggregated to form Lewy bodies. SNCA Protein causes neuronal differentiation and maturation disorders, inhibits neurite outgrowth, reduces neuronal electrical activity through increased gene copy number (such as triploidy) or mutation, and promotes the release of extracellular toxic particles (such as oligomers) by interfering with the autophagy-lysosomal pathway (ALP), thereby inducing inflammatory responses and damage to neighboring cells. SNCA Protein, Human is a recombinant SNCA protein expressed by E. coli without a tag.
There is no specific Pubmed ID mentioned in the paragraph. Amyloid Precursor/Beta-APP40 Protein, Human (His-GST) is the recombinant human-derived Amyloid Precursor/Beta-APP40 protein, expressed by E. coli , with N-His, N-GST labeled tag.
Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA Protein, Human (His) is the recombinant human-derived SNCA protein, expressed by E. coli , with N-6*His labeled tag.
APBA3 Protein, Human (rHuAPBA3, His; Amyloid beta A4 precursor protein-binding family A member 3; APBA3) is an approximately 20.0 kDa APBA3 protein fused to His-tag. APBA3 Protein, Human (His) is an adapter protein that belongs to the X11 family and is involved in signal transduction processes.
TML-6-d3 is the deuterium labeled TML-6. TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloidprecursorprotein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-
BACE1 Antibody (YA1914) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1914), targeting BACE1, with a predicted molecular weight of 56 kDa (observed band size: 68 kDa). BACE1 Antibody (YA1914) can be used for WB, IP experiment in human, mouse, rat background.
Amyloid Precursor Protein Antibody (YA1130) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1130), targeting Amyloid Precursor Protein. Amyloid Precursor Protein Antibody (YA1130) can be used for IHC-P experiment in human background.
Amyloid fibril Protein AA; Amyloid fibrils; AmyloidProtein A; Fibrils; PIG4; SAA 1; SAA 2; Serum Amyloid A ProteinPrecursor
IHC-P
Human
Serum Amyloid A Antibody (YA1168) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1168), targeting Serum Amyloid A. Serum Amyloid A Antibody (YA1168) can be used for IHC-P experiment in human background.
Phospho-Amyloid Precursor Protein (Thr743) Antibody (YA2568) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2568), targeting Phospho-Amyloid Precursor Protein (Thr743), with a predicted molecular weight of 87 kDa (observed band size: 100 kDa). Phospho-Amyloid Precursor Protein (Thr743) Antibody (YA2568) can be used for WB, ICC/IF, IP experiment in human, rat background.
AM-6494 is a potent and orally active BACE1 (efficacious β-site amyloidprecursorprotein cleaving enzyme 1) inhibitor (IC50=0.4 nM) with in vivo selectivity over BACE2 (IC50=18.6 nM) . AM-6494 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cholesterol Excipient is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity. Cholesterol Excipient is a drug delivery carrier based on the lipid environment of the cell membrane. Due to its amphiphilicity, good biocompatibility and biodegradability, it can be used as an excipient in drug preparations. Cholesterol Excipient can self-assemble into delivery systems such as micelles, nanoparticles, and liposomes, and achieve controlled drug release by regulating membrane fluidity or responding to the microenvironment. It has the characteristics of high drug loading efficiency and good biocompatibility. Cholesterol Excipient is mainly used for research in the fields of targeted delivery of anticancer, antibacterial, antiviral drugs and treatment of skin diseases.
Cholesterol itself is also an endogenous regulator involved in the cleavage of amyloidprecursorprotein (APP) mediated by β-secretase and intestinal absorption, as well as an endogenous estrogen-related receptor α (ERRα) agonist. Cholesterol affects the subcellular localization of APP processing enzymes by regulating the cell membrane lipid environment, which can promote the production of β-amyloidprotein and its adsorption and removal by probiotics. It is used to study the pathogenesis of Alzheimer's disease (AD) and the cholesterol-lowering function of probiotics[1][2][3][4][5].
Inquiry Online
Your information is safe with us. * Required Fields.
